InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2021 Annual General Meeting

December 3, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2021 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2021 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.

The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals’ results of the phase IIb study with cobitolimod

October 6, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal The Lancet Gastroenterology and Hepatology. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint and cobitolimod demonstrated an outstanding combination of efficacy and safety.

InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences

August 24, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study will be presented orally at two leading gastroenterology conferences; the United European Gastroenterology Week (UEGW) and the American College of Gastroenterology (ACG) Annual Scientific Meeting. CONDUCT was a phase IIb dose optimisation study, evaluating the first-in-class TLR9 agonist cobitolimod for the treatment of moderate to severe ulcerative colitis. The study met the primary endpoint with an outstanding combination of efficacy and safety.

Update on InDex Pharmaceuticals Holding AB’s (InDex) Annual General Meeting addressing covid-19

April 8, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced that the company plans to hold its Annual General Meeting 2020 as scheduled at 5.00 pm on April 20, 2020, but takes precautionary measures.

· Due to the risk for spread of infection InDex plans to limit the scope of the Annual General Meeting and the presence of the Board of Directors and Management.
· There will be no presentation by the CEO at the Annual General Meeting. InDex plans to provide update via other channels close to the Annual General Meeting.
· No food or refreshments will be served.
· The number of attendees will be limited in accordance with the restrictions in force at the time of the Annual General Meeting.

InDex Pharmaceuticals publishes mechanism of action data for cobitolimod in scientific journal

February 25, 2020 – InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, published in the peer-reviewed Journal of Crohns and Colitis (JCC), shows that the Toll-like receptor 9 (TLR9) agonist cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. The publication has also been highlighted in the journal podcast.

Investor contact

Peter Zerhouni
Peter Zerhouni
+46 8 122 038 50